High-dose chemotherapy for triple negative breast cancer.
De Giorgi
U
U
Istituto Oncologico Romagnolo, Department of Oncology and Hematology, Santa Maria delle Croci Hospital, Ravenna. Electronic address: ugo_degiorgi@yahoo.com.
Rosti
G
G
Istituto Oncologico Romagnolo, Department of Oncology and Hematology, Santa Maria delle Croci Hospital, Ravenna.
Frassineti
L
L
Istituto Oncologico Romagnolo, Department of Oncology, Pierantoni Hospital, Forli, Italy.
Kopf
B
B
Istituto Oncologico Romagnolo, Department of Oncology and Hematology, Santa Maria delle Croci Hospital, Ravenna.
Giovannini
N
N
Istituto Oncologico Romagnolo, Department of Oncology, Pierantoni Hospital, Forli, Italy.
Zumaglini
F
F
Istituto Oncologico Romagnolo, Department of Oncology and Hematology, Santa Maria delle Croci Hospital, Ravenna.
Marangolo
M
M
Istituto Oncologico Romagnolo, Department of Oncology and Hematology, Santa Maria delle Croci Hospital, Ravenna.
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008875:Middle Aged; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000378:metabolism*
D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone